(Q33465315)

27 July 2017

title

Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study (English)

1 reference

27 July 2017

0 references

1 reference

1 reference

Jan Kassubek

3

0 references

author name string

Daniel Ecker

series ordinal

1

1 reference

27 July 2017

Alexander Unrath

series ordinal

2

1 reference

27 July 2017

Michael Sabolek

series ordinal

4

1 reference

27 July 2017

publication date

10 June 2009

1 reference

27 July 2017

1 reference

27 July 2017

volume

9

1 reference

27 July 2017

issue

1

1 reference

23 June 2019

page(s)

23

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2377-9-23

27 July 2017

exact match

0 references

cites work

Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Psychiatric complications in Parkinson disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Psychotic symptoms in Parkinson's disease. From description to etiology

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Prospective study of hallucinations and delusions in Parkinson's disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Visual hallucinations in Parkinson's disease: a review and phenomenological survey

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Hallucinosis in idiopathic Parkinson's disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

[35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Visual hallucinations associated with Parkinson disease.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Visual hallucinations in a geriatric psychiatry clinic: prevalence and associated diagnoses

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

The occurrence of depression in Parkinson's disease. A community-based study.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Parkinson's disease: drug-induced psychiatric states.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Bromocriptine and psychosis: a literature review

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Parkinson's disease in 1984: an update.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Behavioral complications of drug treatment of Parkinson's disease

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Levodopa-induced psychosis: a kindling phenomenon

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

14 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-23

Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-23

Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-23

High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-23

Psychosis related to ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-23

High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-23

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-23

Screening for cognitive impairment: a triage for outpatient care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-23

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-23

The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-23

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-23

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-9-23

The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704166

Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2Asites for PCP-induced locomotion in the rat

31 October 2018

1 reference

12 December 2020

Hallucinations in Parkinson's disease. prevalence, phenomenology and risk factors. Fenelon G* mahieux F, huon R, Ziegler M. Brain 2000;123:733-745

1 reference

12 December 2020

[Dementia in progressive supranuclear paralysis patients]

1 reference

12 December 2020

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial

1 reference

12 December 2020

Psychiatric aspects of Parkinson's disease

1 reference

12 December 2020

The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993

1 reference

12 December 2020

A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease

1 reference

12 December 2020

Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2377-9-23

1 reference

Dimensions Publication ID

27 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2377-9-23

9 September 2019

1 reference

27 July 2017

1 reference